CHANCE - Candesartan in Hypertrophic Cardiomyopathy

Summary

The primary hypothesis of the study is that treatment with AT1-R antagonist in patients with nonobstructive form of HCM will be first save, second will cause regression of myocardial hypertrophy.

Timeline

Start

—

Primary completion

—

Completion

—

Publications

• Penicka M, Gregor P, Kerekes R, Marek D, Curila K, Krupicka J; Candesartan use in Hypertrophic And Non-obstructive Cardiomyopathy Estate (CHANCE) Study Investigators. The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study. J Mol Diagn. 2009 Jan;11(1):35-41. doi: 10.2353/jmoldx.2009.080082. Epub 2008 Dec 12.

Drugs

Indications